Trial · NCT00003644

Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer

NCT00003644, Phase 3, Completed, Gynecologic Oncology Group; results first posted 2019-04-17

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer. Trials, record NCT00003644. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00003644

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer
NCT number: NCT00003644
Status: Completed
Phases: Phase 3
Enrollment: 571 participants, actual
Lead sponsor: Gynecologic Oncology Group
Conditions: Ovarian Cancer
Interventions: carboplatin, paclitaxel
First posted: 2003-01-27
Last updated: 2019-06-04
Results first posted: 2019-04-17

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Progression-free Survival	Up to 5 years	The percent of participants with disease recurrence within 5 years
Primary	Overall Survival	up to 96 months	Number of deaths during study and follow up.
Primary	Number of Participants With Adverse Events Grade 3 or Greater	Throughout study treatment lasting up to 24 weeks	Toxicities, Grade 3 or greater (CTC version 2.0) by treatment arm for all treated participants

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Progression-free Survival	Up to 5 years	Eligible and treated participants	percentage of participants	NUMBER
PRIMARY	Overall Survival	up to 96 months	All eligible and treated participants	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Number of Participants With Adverse Events Grade 3 or Greater	Throughout study treatment lasting up to 24 weeks	All treated participants	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group48

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Progression-free Survival	Paclitaxel + Carboplatin Followed 4 Weeks Later by Paclitaxel		20.4	95% Confidence Interval 15.9 to 25.9	percentage of participants
Progression-free Survival	Paclitaxel + Carboplatin Followed by Observation		23.2	95% Confidence Interval 18.4 to 28.9	percentage of participants
Overall Survival	Paclitaxel + Carboplatin Followed 4 Weeks Later by Paclitaxel		44		Participants
Overall Survival	Paclitaxel + Carboplatin Followed by Observation		53		Participants
Number of Participants With Adverse Events Grade 3 or Greater	Grade 3 & Above Toxicity Paclitaxel + Carboplatin x 24 Cycles	Leukopenia	74		Participants
Number of Participants With Adverse Events Grade 3 or Greater	Grade 3 & Above Toxicity Paclitaxel + Carboplatin x 3 Cycles	Leukopenia	86		Participants
Number of Participants With Adverse Events Grade 3 or Greater	Grade 3 & Above Toxicity Paclitaxel + Carboplatin x 24 Cycles	Thrombocytopenia	12		Participants
Number of Participants With Adverse Events Grade 3 or Greater	Grade 3 & Above Toxicity Paclitaxel + Carboplatin x 3 Cycles	Thrombocytopenia	16		Participants
Number of Participants With Adverse Events Grade 3 or Greater	Grade 3 & Above Toxicity Paclitaxel + Carboplatin x 24 Cycles	Neutropenia	203		Participants
Number of Participants With Adverse Events Grade 3 or Greater	Grade 3 & Above Toxicity Paclitaxel + Carboplatin x 3 Cycles	Neutropenia	196		Participants

1 to 10 of 48Source ClinicalTrials.gov

See all 48 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Paclitaxel + Carboplatin Followed 4 Weeks Later by Paclitaxel	289
Overall Study	STARTED	Paclitaxel + Carboplatin Followed by Observation	282
Overall Study	COMPLETED	Paclitaxel + Carboplatin Followed 4 Weeks Later by Paclitaxel	274
Overall Study	COMPLETED	Paclitaxel + Carboplatin Followed by Observation	268
Overall Study	NOT COMPLETED	Paclitaxel + Carboplatin Followed 4 Weeks Later by Paclitaxel	15
Overall Study	NOT COMPLETED	Paclitaxel + Carboplatin Followed by Observation	14

Source ClinicalTrials.gov

Adverse events78

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Leukopenia	Blood and lymphatic system disorders	Paclitaxel + Carboplatin Followed 4 Weeks Later by Paclitaxel	247	274	247
other	Leukopenia	Blood and lymphatic system disorders	Paclitaxel + Carboplatin Followed by Observation	236	268	236
other	Anema	Blood and lymphatic system disorders	Paclitaxel + Carboplatin Followed 4 Weeks Later by Paclitaxel	219	274	219
other	Anema	Blood and lymphatic system disorders	Paclitaxel + Carboplatin Followed by Observation	209	268	209
other	Thrombocytopenia	Blood and lymphatic system disorders	Paclitaxel + Carboplatin Followed 4 Weeks Later by Paclitaxel	122	274	122
other	Thrombocytopenia	Blood and lymphatic system disorders	Paclitaxel + Carboplatin Followed by Observation	109	268	109
other	Neutropenia	Blood and lymphatic system disorders	Paclitaxel + Carboplatin Followed 4 Weeks Later by Paclitaxel	255	274	255
other	Neutropenia	Blood and lymphatic system disorders	Paclitaxel + Carboplatin Followed by Observation	247	268	247
other	Other Hematologic	Blood and lymphatic system disorders	Paclitaxel + Carboplatin Followed 4 Weeks Later by Paclitaxel	13	274	13
other	Other Hematologic	Blood and lymphatic system disorders	Paclitaxel + Carboplatin Followed by Observation	13	268	13

1 to 10 of 78Source ClinicalTrials.gov

See all 78 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Paclitaxel + Carboplatin Followed 4 Weeks Later by Paclitaxel	44	274
Total, all-cause mortality	Paclitaxel + Carboplatin Followed by Observation	53	268
Total, other adverse events	Paclitaxel + Carboplatin Followed 4 Weeks Later by Paclitaxel	271	274
Total, other adverse events	Paclitaxel + Carboplatin Followed by Observation	265	268
Total, serious adverse events	Paclitaxel + Carboplatin Followed 4 Weeks Later by Paclitaxel	7	274
Total, serious adverse events	Paclitaxel + Carboplatin Followed by Observation	5	268

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
21529904	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Paclitaxel + Carboplatin Followed 4 Weeks Later by Paclitaxel vs Paclitaxel + Carboplatin Followed by Observation: Overall Survival	Trial comparisons
Paclitaxel + Carboplatin Followed 4 Weeks Later by Paclitaxel vs Paclitaxel + Carboplatin Followed by Observation: deaths from any cause	Trial comparisons
Paclitaxel + Carboplatin Followed 4 Weeks Later by Paclitaxel vs Paclitaxel + Carboplatin Followed by Observation: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00003644

GET https://conductscience.org/api/trials/v1/NCT00003644/results?page=2

API reference For AI assistants